🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 50 of 757 · Phase 3 first, then by program name

  1. Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)

    United Therapeutics Europe Ltd

    Cardiovascular Disease

    phase 3 mab completed

    1 trial

  2. Elaprase 2 mg/ml concentrate for solution for infusion

    Denali Therapeutics

    Mucopolysaccharidosis Type II [MPS II]

    phase 3 small molecule active

    1 trial

  3. Elective nodal irradiation (ENI)

    China SXT Pharmaceuticals

    Esophageal Squamous Cell Carcinoma

    phase 3 other active

    1 trial

  4. Eligard 22,5 mg poeder en oplosmiddel voor oplossing voor injectie

    Disc Medicine

    Patients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastases

    phase 3 small molecule active

    1 trial

  5. Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat, Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat

    Genzyme Europe B.V.

    Gaucher's disease type I; Gaucher's disease type III

    phase 3 small molecule active

    1 trial

  6. Eliquis 5 mg film-coated tablets, ACETYLSALICYLIC ACID

    Pari Pharma GmbH

    Aortic bioprothesis implanted patient for valvular heart disease

    phase 3 small molecule active

    1 trial

  7. Eloralintide, Eloralintide, Eloralintide, Placebo to match LY, Eloralintide

    Eli Lilly Co.

    Overweight, Obesity, Sleep Apnea, Obstructive

    phase 3 small molecule active

    1 trial

  8. Eloralintide, Eloralintide, Placebo to match LY, Eloralintide, Eloralintide

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 small molecule active

    1 trial

  9. Eloralintide, Placebo to match LY, Eloralintide, Eloralintide, Eloralintide

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  10. Elritercept

    Takeda Pharmaceuticals International AG

    Myelodysplastic Syndromes

    phase 3 small molecule active

    2 trials

  11. Elritercept

    Takeda Pharmaceuticals International AG

    Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  12. Eltrombopag 25 MG Oral Tablet

    First Tracks Biotherapeutics

    Stem Cell Transplant Complications

    phase 3 small molecule completed

    1 trial

  13. Emicizumab

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 small molecule active

    1 trial

  14. Emixustat

    BRIGHT MINDS BIOSCIENCES INC.

    Stargardt Disease

    phase 3 small molecule completed

    1 trial

  15. Empagliflozin 10 MG

    COLLEGIUM PHARMACEUTICAL, INC

    Acute Decompensated Heart Failure

    phase 3 small molecule active

    1 trial

  16. Empagliflozin 10 mg

    United Therapeutics Europe Ltd

    Acute Myocardial Infarction

    phase 3 small molecule completed

    1 trial

  17. Empagliflozin 20 mg

    COLLEGIUM PHARMACEUTICAL, INC

    Metabolic Syndrome

    phase 3 small molecule active

    1 trial

  18. Empliciti 400 mg powder for concentrate for solution for infusion., DARZALEX 1800 mg solution for injection, Alnuctamab, Imnovid 2 mg hard capsules, Alnuctamab, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Fortecortin® Inject 8 mg Injektionslösung in einer Ampulle, DEXAMETHASONE, Imnovid 4 mg hard capsules

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  19. Empowered Relief On-Demand

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Pain

    phase 3 other completed

    1 trial

  20. Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe

    Mabxience Research SL

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  21. Enbrel 50 mg solution for injection in pre-filled syringe, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab 0.5 mL Varioject Placebo, Enbrel 25 mg powder and solvent for solution for injection

    Janssen-Cilag International N.V.

    Chronic Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  22. Encaleret

    BridgeBio Oncology Therapeutics

    Autosomal Dominant Hypocalcemia Type 1 (ADH1)

    phase 3 small molecule active

    1 trial

  23. Encaleret

    BridgeBio Oncology Therapeutics

    Autosomal Dominant Hypocalcemia (ADH)

    phase 3 small molecule active

    2 trials

  24. Endoscopic submucosal dissection

    United Therapeutics Europe Ltd

    Colorectal Neoplasms

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources